Patents by Inventor Gil G. Mor
Gil G. Mor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200009108Abstract: The present invention provides the eutomeric isomer of the compound of formula (I), or a salt or solvate thereof, which can be used to treat epithelial cancer in a subject. In certain embodiments, the compound of formula (I) can be used in combination with AICAR and/or cisplatin.Type: ApplicationFiled: March 12, 2019Publication date: January 9, 2020Inventors: Gil G. MOR, Ayesha ALVERO
-
Patent number: 10265294Abstract: The present invention provides the eutomeric isomer of the compound of formula (I), or a salt or solvate thereof, which can be used to treat epithelial cancer in a subject. In certain embodiments, the compound of formula (I) can be used in combination with AICAR and/or cisplatin.Type: GrantFiled: March 28, 2017Date of Patent: April 23, 2019Assignee: Yale UniversityInventors: Gil G. Mor, Ayesha Alvero
-
Patent number: 10168334Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.Type: GrantFiled: September 16, 2016Date of Patent: January 1, 2019Assignee: Yale UniversityInventors: Gil G. Mor, David C. Ward, Patricia Bray-Ward
-
Publication number: 20170281588Abstract: The present invention provides the eutomeric isomer of the compound of formula (I), or a salt or solvate thereof, which can be used to treat epithelial cancer in a subject. In certain embodiments, the compound of formula (I) can be used in combination with AICAR and/or cisplatin.Type: ApplicationFiled: March 28, 2017Publication date: October 5, 2017Inventors: Gil G. MOR, Ayesha ALVERO
-
Publication number: 20170138950Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.Type: ApplicationFiled: September 16, 2016Publication date: May 18, 2017Inventors: GIL G. MOR, DAVID C. WARD, PATRICIA BRAY-WARD
-
Patent number: 9470688Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.Type: GrantFiled: January 22, 2015Date of Patent: October 18, 2016Assignee: Yale UniversityInventors: Gil G. Mor, David C. Ward, Patricia Bray-Ward
-
Publication number: 20160018402Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.Type: ApplicationFiled: January 22, 2015Publication date: January 21, 2016Applicant: Yale UniversityInventors: Gil G. Mor, David C. Ward, Patricia Bray-Ward
-
Publication number: 20150233929Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.Type: ApplicationFiled: January 22, 2015Publication date: August 20, 2015Applicant: Yale UniversityInventors: Gil G. Mor, David C. Ward, Patricia Bray-Ward
-
Patent number: 8975379Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.Type: GrantFiled: December 22, 2009Date of Patent: March 10, 2015Assignee: Yale UniversityInventors: Gil G. Mor, David C. Ward, Patricia Bray-Ward
-
Publication number: 20120251630Abstract: Provided herein is a method of reducing incidences of cancer recurrence. The method involves administering to an individual in cancer remission an isoflavonoid. In specific instances, the treated individual is in remission from epithelial cancer, such as ovarian cancer or breast cancer.Type: ApplicationFiled: March 29, 2012Publication date: October 4, 2012Applicant: MARSHALL EDWARDS, INC.Inventors: Ayesha B. Alvero, Daniel P. Gold, Gil G. Mor
-
Patent number: 7985538Abstract: Described herein is a cellular marker, MyD88, useful for assessing an individual's (patient's) sensitivity (or resistance) to chemotherapy, particularly sensitivity (or resistance) to chemotherapeutic drugs, such as plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). As described herein, Applicants provide a method by which it is possible to determine whether an individual (cancer cells in an individual) is sensitive to chemotherapy with plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). Early identification of chemoresistance in patients with cancer is of utmost importance, particularly since it makes it possible to provide the most appropriate therapy.Type: GrantFiled: February 23, 2007Date of Patent: July 26, 2011Assignee: Yale UniversityInventor: Gil G. Mor
-
Publication number: 20100311047Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.Type: ApplicationFiled: December 22, 2009Publication date: December 9, 2010Applicant: Yale UniversityInventors: Gil G. Mor, David C. Ward, Patricia Bray-Ward
-
Patent number: 7790463Abstract: The present invention provides methods and compositions related to biomarker profiles for each trimester of pregnancy. The present invention also provides methods for identifying patients at risk of developing a complication of pregnancy, such as preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.Type: GrantFiled: February 2, 2006Date of Patent: September 7, 2010Assignees: Yale University, The United States of America as represented by the Department of Health and Human ServicesInventors: Gil G. Mor, Donna Neale, Roberto Romero
-
Patent number: 7666583Abstract: The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.Type: GrantFiled: January 18, 2005Date of Patent: February 23, 2010Assignee: Yale UniversityInventors: Gil G. Mor, David C. Ward, Patricia Bray-Ward
-
Publication number: 20090220427Abstract: Described herein is a cellular marker, MyD88, useful for assessing an individual's (patient's) sensitivity (or resistance) to chemotherapy, particularly sensitivity (or resistance) to chemotherapeutic drugs, such as plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). As described herein, Applicants provide a method by which it is possible to determine whether an individual (cancer cells in an individual) is sensitive to chemotherapy with plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). Early identification of chemoresistance in patients with cancer is of utmost importance, particularly since it makes it possible to provide the most appropriate therapy.Type: ApplicationFiled: February 23, 2007Publication date: September 3, 2009Applicant: Yale UniversityInventor: Gil G. Mor
-
Patent number: 7541182Abstract: The present invention provides methods for identifying patients at risk of developing preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.Type: GrantFiled: February 13, 2004Date of Patent: June 2, 2009Assignees: Yale University, The United States of America as represented by the Department of Health and Human ServicesInventors: Gil G. Mor, Donna Neale, Roberto Romero